Traders Alert: Endo Int'l Plc (ENDP)

Marco Green
August 12, 2017

As of the last earnings report the EPS was $-15.20 and is estimated to be $3.52 for the current year with 223,158,000 shares now outstanding.

The company is so far trading up since yesterday's close of $7.55.

A number of equities analysts recently issued reports on ENDP shares. Canaccord Genuity set a $14.00 target price on Endo International PLC and gave the company a hold rating in a report on Monday, May 1st. Oppenheimer Holdings, Inc. reiterated a "hold" rating on shares of Endo International PLC in a research note on Sunday, July 23rd.

Currently, the analyst consensus on Endo International is Hold and the average price target is $13.09, representing a 73.4% upside.

Additionally on 8/09/17 Deutsche Bank "Maintained" Endo Int'l Plc (NASDAQ:ENDP) to Buy setting price target at $13 and on 6/16/17 Cantor Fitzgerald "Initiates Coverage On" the stock to Neutral at $12. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the company's stock. In current trading day Leju Holdings Limited (LEJU) stock confirmed the flow of -4.22% with the final price of $1.59.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another website, it was illegally stolen and republished in violation of global trademark & copyright laws. The legal version of this piece of content can be read at

Shares of Endo International PLC (NASDAQ ENDP) opened at 7.65 on Wednesday. The brokerage now has a "buy" rating on the stock. The stock's market capitalization is $1.71 billion.

According to analysts Endo Int'l Plc (NASDAQ:ENDP)'s minimum EPS for the current quarter is at $0.55 and can go high up to $0.8. The company has a 50-day moving average price of $11.04 and a 200 day moving average price of $11.59.

Endo Int'l Plc (NASDAQ:ENDP) 52-week high price stands at $24.93 and low price stands at $7.81, its price distance from 52-week high is -69.72% while its distance from 52-week low price is -3.33%. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.74 by $0.19. The firm had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. During the same period in the previous year, the business earned $0.86 EPS. Ameriprise Financial Inc. boosted its position in Endo International PLC by 4.9% in the second quarter. Macquarie Group Ltd. increased its position in Endo International PLC by 132.1% in the fourth quarter. Parametric Portfolio Associates LLC now owns 398,099 shares of the company's stock worth $4,447,000 after buying an additional 62,822 shares during the last quarter. OppenheimerFunds Inc. increased its position in Endo International PLC by 182.9% in the first quarter. As of quarter end Wells Fargo & Company/mn had acquired a total of 78,536 shares growing its stake by 25.3%. Point View Wealth Management Inc. boosted its stake in Endo International PLC by 12.3% in the first quarter. Teachers Advisors LLC now owns 840,470 shares of the company's stock worth $9,388,000 after buying an additional 15,928 shares during the period. Its investment was valued at $37,256,000 a decrease of 7.7% as of the end of the quarter.

In other Endo International PLC news, COO Terrance J. Coughlin acquired 20,000 shares of Endo International PLC stock in a transaction dated Thursday, August 10th. The total value of its holdings decreased 5.6%. Capstone Asset Management Co. now owns 32,035 shares of the company's stock worth $358,000 after buying an additional 960 shares during the period. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Institutional investors own 93.00% of the company's stock.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services.

Other reports by Click Lancashire

Discuss This Article